Association between clinical factors and dose modification strategies in the treatment with ustekinumab for moderate-to-severe plaque psoriasis

References

• Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377–385.
   PubMed Web of Science ®Google Scholar
• Smith CH, Jabbar-Lopez ZK, Yiu ZZ, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017;177:628–636.
   PubMed Web of Science ®Google Scholar
• Puig L, Carrascosa JM, Carretero G, et al. Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Actas Dermosifiliogr. 2013;104:694–709.
   PubMedGoogle Scholar
• Ramírez-Herráiz E, Escudero-Vilaplana V, Alañón-Plaza E, et al. Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice. Clin Exp Rheumatol. 2013;31:559–565.
   PubMed Web of Science ®Google Scholar
• Den Broeder AA, Creemers MC, Van Gestel AM, et al. Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNFalpha. Rheumatology. 2002;41:638–642.
   PubMed Web of Science ®Google Scholar
• López-Ferrer A, Vilarrasa E, Gich IJ, et al. Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre. Br J Dermatol. 2013;169:1141–1147.
   PubMed Web of Science ®Google Scholar
• Carrascosa JM, Garcia-Doval I, Pérez-Zafrilla B, et al. Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: a cross-sectional study in clinical practice. J Dermatolog Treat. 2015;26:502–506.
   PubMed Web of Science ®Google Scholar
• Romero-Jiménez RM, Escudero-Vilaplana V, Baniandres Rodriguez O, et al. Efficiency of biological therapies in patients with moderate to severe psoriasis in clinical practice: impact of a pharmacotherapeutic protocol. J Dermatolog Treat. 2016;27:198–202.
   PubMed Web of Science ®Google Scholar
• Iskandar IY, Ashcroft DM, Warren RB, et al. Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Br J Dermatol. 2017;176:1297–1307.
   PubMedGoogle Scholar
• European Public Assessment Reports [Internet]. London: European Medicines Agency. Summary of product characteristics: stelara. [cited 2017 Oct]. Available form: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Prod-uct_Information/human/000958/WC500058513.pdf
   Google Scholar
• Menting SP, van den Reek JM, Baerveldt EM, et al. The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting. Br J Dermatol. 2015;173:855–857.
   PubMed Web of Science ®Google Scholar
• Chiu HY, Chu TW, Cheng YP, et al. The association between clinical response to ustekinumab and immunogenicity to ustekinumab and prior adalimumab. PLoS One. 2015;10:e0142930.
   PubMed Web of Science ®Google Scholar
• Sorensen EP, Fanucci KA, Saraiya A, et al. Tumor necrosis factor inhibitor primary failure predicts decreased ustekinumab efficacy in psoriasis patients. J Drugs Dermatol. 2015;14:893–898.
   PubMed Web of Science ®Google Scholar
• Takahashi N, Noda S, Taniguchi T, et al. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases. Int J Dermatol. 2015;54:1194–1198.
   PubMed Web of Science ®Google Scholar
• Atalay S, van den Reek JMPA, van Vugt LJ, et al. Tight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial. BMC Dermatol. 2017;17:6.
   PubMed Web of Science ®Google Scholar
• García-Doval I, Pérez-Zafrilla B, Ferrandiz C, et al. Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort. J Dermatolog Treat. 2016;27:203–209.
   PubMed Web of Science ®Google Scholar
• Di Lernia V, Ricci C, Lallas A, et al. Clinical predictors of non-response to any tumor necrosis factor (TNF) blockers: a retrospective study. J Dermatolog Treat. 2014;25:73–74.
   PubMed Web of Science ®Google Scholar
• Umezawa Y, Saeki H, Nakagawa H. Some clinical factors affecting quality of the response to ustekinumab for psoriasis. J Dermatol. 2014;41:690–696.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665–1674.
   PubMed Web of Science ®Google Scholar
• Puig L, Ruiz-Salas V. Long-term efficacy, safety and drug survival of ustekinumab in a Spanish cohort of patients with moderate to severe plaque psoriasis. Dermatology. 2015;230:46–54.
   PubMed Web of Science ®Google Scholar
• Talamonti M, Galluzzo M, Bianchi L, et al. What happened after the clinical trials: long-term safety and efficacy of ustekinumab in daily clinical practice. Dermatology. 2014;229:324–332.
   PubMed Web of Science ®Google Scholar
• Puig L. Treatment of moderate to severe plaque psoriasis with biologics: analysis of the additional cost of temporary dose escalation vs. switch to another biologic after failure of maintenance therapy. Actas Dermosifiliogr. 2014;105:401–402.
   PubMedGoogle Scholar
• Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362:118–128.
   PubMed Web of Science ®Google Scholar
• Papp K, Gottlieb AB, Naldi L, et al. Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol. 2015;14:706–714.
   PubMed Web of Science ®Google Scholar